Organovo Holdings has a Cash Ratio of 3.11. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Organovo Holdings's Cash Ratio or its related term are showing as below:
ONVO'
s Cash Ratio Range Over the Past 10 Years
Min: 3.11 Med: 13.88 Max: 51.82
Current: 3.11
During the past 12 years, Organovo Holdings's highest Cash Ratio was 51.82. The lowest was 3.11. And the median was 13.88.
ONVO's Cash Ratio is ranked better than 51.93% of 1525
companies
in the Biotechnology industry
Industry Median: 2.85
vs ONVO: 3.11
Organovo Holdings Cash Ratio Historical Data
The historical data trend for Organovo Holdings's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Organovo Holdings's Cash Ratio
For the Biotechnology subindustry, Organovo Holdings's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Organovo Holdings's Cash Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Organovo Holdings's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Organovo Holdings's Cash Ratio falls into.
Organovo Holdings Cash Ratio Calculation
The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.
Organovo Holdings's Cash Ratio for the fiscal year that ended in Mar. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Organovo Holdings (NAS:ONVO) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Organovo Holdings Cash Ratio Related Terms
Thank you for viewing the detailed overview of Organovo Holdings's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Organovo Holdings (Organovo Holdings) Business Description
Organovo Holdings Inc is a biotechnology company, which designs and creates functional and three-dimensional human tissues for medical research and therapeutic applications. It also develops and commercializes a platform technology for the generation of three-dimensional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company collaborates with pharmaceutical and academic partners to develop human biological disease models in three dimensions. Organovo's key instrument platform is the NovoGen Bioprinter. The firm's 3-D bioprinting technologies create tissues using living cells and biocompatible hydrogels.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ONVO has been successfully added to your 